The Briefing Room – what next for healthcare communications?

Finally, there are many risks associated with longer stays: infections; blood clots; muscle weakening and pressure sores, to ...

Ten exciting new pharmaceutical drugs emerging in 2026 ...

The Oxford-based biotechnology company Theolytics has been awarded €8 million in non-dilutive grant funding from Horizon ...

HUTCHMED has initiated a global phase 1/2a clinical trial of HMPL‑A580, its second antibody‑targeted therapy conjugate, in patients with unresectable, advanced or metastatic solid tumours in China and ...

The fear that machines would replace humans within months was quickly replaced with a new narrative that, far from making ...

Too often, people suffer in silence because of deeply rooted taboos around certain health conditions. While these stigmas are ...

For decades, the UK’s pharmaceutical and biotech sectors have been leaders in discovery and innovation. Yet as the cost of ...

The NHS in 2026 is facing a familiar but intensifying oncology challenge. Our data at HSJ Information shows rising incidence, ...

The approvals are supported by the REAL8 study, which showed Sogroya was non‑inferior to daily growth hormone therapy across all three indications. Adverse reactions occurring in at least 10% of ...

Bioxytran has announced encouraging results from a randomized, double‑blind, placebo‑controlled phase 1b/2a study of its oral ...

Nucleome Therapeutics, a company tackling the molecular causes of inflammatory diseases through a breakthrough approach to 3D human genetics, has announced the appointment of Dr Michelle Morrow as ...